1. Misra A, Phadte A, Subramani V, Dhanawat A, Menon S, Arora A, Nagarajan R, Maitre P, Pal M, Joshi A, Lila A, Prakash G, Murthy V (2026). Contemporary management of adrenocortical carcinoma: A narrative review. Urologic Oncology: Seminars and Original Investigations.

2. Bhandare MS (2026). Structured Adaptability in HPB Cancer Surgery: Precision Beyond Technical Uniformity. Annals of Surgical Oncology.

3. Bhandare MS, Nandy K, Parray AM, Pawar A, Padhy A, Menon V, Chopde A, Chaudhari V, Shrikhande SV (2026). Interplay of postpancreatectomy acute pancreatitis, postoperative pancreatic fistula, and mortality after pancreatoduodenectomy: Insight from a comprehensive cohort study of 1,594 patients and development of predictive nomograms. Journal of the American College of Surgeons 242(6):1538-1552.

4. Dwivedi P, Barage S, Jha AK, Agrawal A, Rangarajan, V. (2026). External Validation of PET Radiomics-Based ML Model for Non-Invasive Lung Cancer Subtype Classification. Biomedical & Pharmacology Journal, 19(1), 625.

5. Kashid SR, Budrukkar A, Swain M, Laskar SG, Murthy V, Gupta T, Sasidharan A, Patil V, Joshi A, Noronha V, Mittal N, Mahimkar M, Patil A, Patel U, Sinha S, Kumar A, Menon N, Bal M, Prabhash K, Agarwal JP. Prognostic Factors in Oropharyngeal Cancer Treated With Definitive Chemoradiotherapy. Cancer Medicine.;15(5):e71854. .

6. Gupta S, Rajendran A, Chichra A, Qureshi A (2026). Simultaneous Presentation of Hemophagocytic Lymphohistiocytosis and Classical Hodgkin's Lymphoma in a Patient with Underlying Germline Homozygous STXBP2 Mutation. Mediterranean Journal of Hematology and Infectious Diseases. 18(1):e2026043.

Thesis
Akash Maity. 2026. Uncovering the Molecular Pathogenesis of Acute Promyelocytic Leukemia Associated Coagulopathy. ( LIFE09202104023) (Guide: Dr. Syed K Hasan)

Suhail Ahmad. 2025. Integrative Analysis to Understand the Mechanism of Hormone Therapy Resistance in Breast Cancer. (LIFEE09201704014)(Guide: Dr. Syed K Hasan)

The Mouse Phenome Database enables the integration of genomic and phenomic data by providing access to primary experimental data, well-documented data collection protocols and analysis tools.

DiPersio JF, Koehne G, Shah NN, Bernard L, Suh HC, Koura D, Tamari R, Mushtaq MU, Maakaron J, Rimando J, Kennedy VE, Patel SS, Hudson C, Loken MR, Slapak CA, Lloyd DM, Stanizzi DA, Lee-Sundlov MM, Thosar S, Mundelboim G, Guo G, Ge HG, Li BE, Xavier-Ferrucio J, Hyzy SL, Lin MI, Raffel GD, Cooper BW (2026). CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial. Nature Medicine.

In 2015, FDA approved talimogene laherparepvec (T-VEC) for the treatment of some patients with metastatic melanoma that cannot be surgically removed.

2026 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)